IN2012DN02692A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02692A IN2012DN02692A IN2692DEN2012A IN2012DN02692A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A IN 2692DEN2012 A IN2692DEN2012 A IN 2692DEN2012A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A
- Authority
- IN
- India
- Prior art keywords
- subunit
- immunity against
- inducing immunity
- antigenic peptides
- antibody
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000036039 immunity Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 102000006354 HLA-DR Antigens Human genes 0.000 abstract 1
- 108010058597 HLA-DR Antigens Proteins 0.000 abstract 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000005585 Poxviridae Infections Diseases 0.000 abstract 1
- 241000700647 Variola virus Species 0.000 abstract 1
- 108010067390 Viral Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 229940127121 immunoconjugate Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 102000044166 interleukin-18 binding protein Human genes 0.000 abstract 1
- 108010070145 interleukin-18 binding protein Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25836909P | 2009-11-05 | 2009-11-05 | |
| US25872909P | 2009-11-06 | 2009-11-06 | |
| US12/754,140 US8722047B2 (en) | 2005-03-03 | 2010-04-05 | Humanized anti-HLA-DR antibodies |
| US12/754,740 US8562988B2 (en) | 2005-10-19 | 2010-04-06 | Strategies for improved cancer vaccines |
| US37805910P | 2010-08-30 | 2010-08-30 | |
| PCT/US2010/054668 WO2011056721A2 (en) | 2009-11-05 | 2010-10-29 | Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02692A true IN2012DN02692A (OSRAM) | 2015-09-04 |
Family
ID=43970701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2692DEN2012 IN2012DN02692A (OSRAM) | 2009-11-05 | 2010-10-29 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2496256A4 (OSRAM) |
| CN (1) | CN102573902A (OSRAM) |
| AU (1) | AU2010315432A1 (OSRAM) |
| CA (1) | CA2776563A1 (OSRAM) |
| IN (1) | IN2012DN02692A (OSRAM) |
| WO (1) | WO2011056721A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012228100B2 (en) | 2011-03-17 | 2016-09-08 | The University Of Birmingham | Re-directed immunotherapy |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2014047124A1 (en) * | 2012-09-18 | 2014-03-27 | University Of Washington Through Its Center For Commercialization | Compositions and methods for delivery of antigens to plasmacytoid dendritic cells |
| EP3253419A1 (en) | 2015-02-02 | 2017-12-13 | The University of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| JP7073258B2 (ja) | 2015-11-19 | 2022-05-23 | レビトープ リミテッド | 望ましくない細胞の再指向性死滅に対する二成分系のための機能的抗体断片相互補完 |
| CN109187982B (zh) * | 2018-08-02 | 2021-06-04 | 浙江康佰裕生物科技有限公司 | 一种tlr类疫苗佐剂的筛选和鉴定方法 |
| CN109172818B (zh) * | 2018-08-02 | 2021-10-22 | 浙江康佰裕生物科技有限公司 | 一种蛋白牛痘疫苗及其效力检测方法 |
| CA3117378A1 (en) * | 2018-10-22 | 2020-04-30 | Icellkealex Therapeutics Llc | Mutant vaccinia viruses and use thereof |
| CN111474339A (zh) * | 2020-04-17 | 2020-07-31 | 浙江康佰裕生物科技有限公司 | 一种利用荧光标记痘病毒颗粒的方法及其应用 |
| EP4142782A1 (en) * | 2020-04-27 | 2023-03-08 | Genovie AB | Methods to generate vaccine compositions that prime human leukocyte antigen class i restricted cd8 t-cell responses against viral non-virion-integral derived epitopes |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5194254A (en) * | 1986-05-06 | 1993-03-16 | Connaught Laboratories Limited | Enhancement of antigen immunogenicity |
| WO1994006469A1 (en) * | 1992-09-18 | 1994-03-31 | La Jolla Institute For Allergy And Immunology | Hiv fusion polypeptide |
| ATE395422T1 (de) * | 1995-06-07 | 2008-05-15 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
| JPH11506336A (ja) * | 1995-06-07 | 1999-06-08 | コノート ラボラトリーズ リミテッド | 免疫系選択細胞への抗原送達のためのキメラ抗体 |
| US6224870B1 (en) * | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| US7534866B2 (en) * | 2005-10-19 | 2009-05-19 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
| US7666400B2 (en) * | 2005-04-06 | 2010-02-23 | Ibc Pharmaceuticals, Inc. | PEGylation by the dock and lock (DNL) technique |
| US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
| EP1483294B2 (en) * | 2002-03-01 | 2019-10-30 | Immunomedics, Inc. | Internalizing anti-cd74 antibodies and methods of use |
| US7432342B2 (en) * | 2002-05-03 | 2008-10-07 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof and related documents |
| US7906118B2 (en) * | 2005-04-06 | 2011-03-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology |
| WO2004094613A2 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
| BRPI0607486B8 (pt) * | 2005-03-03 | 2021-05-25 | Immunomedics Inc | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. |
| AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
| CN101484182B (zh) * | 2005-04-06 | 2014-06-11 | Ibc药品公司 | 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途 |
| US20090269365A1 (en) * | 2005-04-20 | 2009-10-29 | University Of Washington | Immunogenic vaccinia peptides and methods of using same |
| EP1937851A4 (en) * | 2005-10-19 | 2010-08-25 | Ibc Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR PRODUCING BIOACTIVE GROUPS OF INCREASED COMPLEXITY AND THEIR USE |
| EP1959993B1 (en) * | 2005-12-16 | 2014-11-19 | IBC Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| CA2651285C (en) * | 2006-05-15 | 2014-08-19 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| CN102119175A (zh) * | 2008-04-10 | 2011-07-06 | Ibc药品公司 | 采用停靠与锁(dnl)技术制备具有增强的药物动力学的四聚细胞因子的模块方法 |
-
2010
- 2010-10-29 IN IN2692DEN2012 patent/IN2012DN02692A/en unknown
- 2010-10-29 EP EP10828938.0A patent/EP2496256A4/en not_active Withdrawn
- 2010-10-29 AU AU2010315432A patent/AU2010315432A1/en not_active Abandoned
- 2010-10-29 WO PCT/US2010/054668 patent/WO2011056721A2/en not_active Ceased
- 2010-10-29 CN CN2010800474188A patent/CN102573902A/zh active Pending
- 2010-10-29 CA CA2776563A patent/CA2776563A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2776563A1 (en) | 2011-05-12 |
| EP2496256A2 (en) | 2012-09-12 |
| AU2010315432A1 (en) | 2012-04-12 |
| WO2011056721A2 (en) | 2011-05-12 |
| WO2011056721A3 (en) | 2011-10-13 |
| CN102573902A (zh) | 2012-07-11 |
| EP2496256A4 (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02692A (OSRAM) | ||
| WO2020193688A3 (en) | Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof | |
| MX350274B (es) | Vacunas para hsv-2. | |
| MX2025008006A (es) | Vacunas novedosas del vph16, composiciones y metodos de uso de las mismas | |
| DK2280721T3 (da) | Indoleamin-2, 3-dioxygenasebaseret immunterapi | |
| WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
| CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
| IN2014DN10288A (OSRAM) | ||
| WO2012034025A3 (en) | Human cytomegalovirus vaccine | |
| PE20190420A1 (es) | Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
| MX2008016036A (es) | Vacuna viral recombinante. | |
| MX363667B (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
| EA201892735A1 (ru) | Состав вакцины против hiv | |
| MY170659A (en) | Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
| WO2007008918A3 (en) | Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof | |
| MX389111B (es) | Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso. | |
| EA201071366A1 (ru) | Комбинированная вакцина против кори и вируса папилломы человека | |
| NZ601609A (en) | Vaccine vectors and methods of enhancing immune responses | |
| WO2008134643A3 (en) | Trypanosoma antigens, vaccine compositions, and related methods | |
| ZA201603187B (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| WO2008054535A3 (en) | Novel influenza m2 vaccines | |
| MY187896A (en) | Dengue virus vaccine compositions and methods of use thereof | |
| PT1951300E (pt) | Modificação do equilíbrio de th1/th2 em vacinas da influenza fragmentadas com adjuvantes |